Status:
WITHDRAWN
Dosing Intervals of Opioid Medication for Chronic Pain
Lead Sponsor:
University Health Network, Toronto
Collaborating Sponsors:
Canadian Society of Hospital Pharmacists
Conditions:
Chronic Pain
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
This study is to determine the feasibility of an n-of-1, randomized, double blind, placebo controlled case series to examine effects of extended release opioids when used at intervals shorter than rec...
Eligibility Criteria
Inclusion
- \>18 years old
- willing and capable to give written informed consent
- diagnosis of chronic pain (\> 3 months)
- current prescription for oxycodone controlled release or hydromorphone controlled release or morphine sustained release for pain
- Using extended release opioids at intervals less than 12 hours/ more than twice daily
Exclusion
- ongoing acute pain episode
- use of immediate release opioids that contribute to more than 20% of their total daily opioid dose
- total daily morphine equivalent dose \>400mg
- actively tapering their opioid dose
- use of multiple extended release opioid products
- unstable psychological diagnosis (using the Psychosocial Screening Interview Guide)
- outstanding or planned litigation related to pain
- pregnancy or lactation in women
- history of coronary artery disease
- active tapering or titration of benzodiazepines or cannabinoids
- positive urine drug screen for amphetamines, barbiturates, cocaine, methamphetamine, methadone, phencyclidine, propoxyphene or unexpected opioids or benzodiazepines
- using M-Eslon
- using long acting hydromorphone
- using Kadian
Key Trial Info
Start Date :
May 1 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 8 2020
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT04132011
Start Date
May 1 2019
End Date
March 8 2020
Last Update
March 27 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University Health Network
Toronto, Ontario, Canada, M5G 2A2